| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 30 | 2026 | 225 | 7.110 |
Why?
|
| Vaccination | 52 | 2026 | 725 | 6.000 |
Why?
|
| Drug Overdose | 11 | 2026 | 62 | 3.930 |
Why?
|
| Immunization Schedule | 16 | 2025 | 127 | 3.770 |
Why?
|
| Analgesics, Opioid | 14 | 2025 | 239 | 3.320 |
Why?
|
| Opioid-Related Disorders | 8 | 2026 | 174 | 3.250 |
Why?
|
| Infant | 53 | 2026 | 1212 | 2.700 |
Why?
|
| Influenza Vaccines | 21 | 2024 | 300 | 2.560 |
Why?
|
| Humans | 130 | 2026 | 16832 | 2.530 |
Why?
|
| Social Media | 4 | 2021 | 11 | 2.200 |
Why?
|
| Child, Preschool | 48 | 2026 | 1430 | 2.120 |
Why?
|
| Parents | 10 | 2021 | 298 | 2.110 |
Why?
|
| Female | 84 | 2026 | 12193 | 1.810 |
Why?
|
| Male | 72 | 2026 | 9556 | 1.790 |
Why?
|
| Influenza, Human | 14 | 2024 | 292 | 1.710 |
Why?
|
| Narcotic Antagonists | 4 | 2026 | 23 | 1.650 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2024 | 353 | 1.620 |
Why?
|
| Health Knowledge, Attitudes, Practice | 12 | 2021 | 352 | 1.510 |
Why?
|
| Naltrexone | 2 | 2026 | 16 | 1.510 |
Why?
|
| United States | 49 | 2026 | 3858 | 1.480 |
Why?
|
| Aluminum | 4 | 2026 | 15 | 1.440 |
Why?
|
| Cohort Studies | 32 | 2026 | 2396 | 1.410 |
Why?
|
| Vaccines, Inactivated | 9 | 2020 | 73 | 1.300 |
Why?
|
| Child | 37 | 2022 | 2433 | 1.280 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2021 | 116 | 1.210 |
Why?
|
| Internet | 4 | 2020 | 207 | 1.180 |
Why?
|
| Retrospective Studies | 28 | 2024 | 2463 | 1.170 |
Why?
|
| Adult | 41 | 2026 | 7255 | 1.140 |
Why?
|
| Opiate Substitution Treatment | 2 | 2026 | 53 | 1.130 |
Why?
|
| Mothers | 2 | 2020 | 104 | 1.130 |
Why?
|
| Consumer Health Information | 3 | 2020 | 12 | 1.130 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2024 | 158 | 1.120 |
Why?
|
| Buprenorphine | 2 | 2026 | 50 | 1.120 |
Why?
|
| Colorado | 14 | 2025 | 171 | 1.110 |
Why?
|
| Treatment Refusal | 6 | 2015 | 30 | 1.090 |
Why?
|
| Chronic Pain | 3 | 2025 | 125 | 1.050 |
Why?
|
| Rotavirus Vaccines | 5 | 2020 | 53 | 1.040 |
Why?
|
| Patient Safety | 2 | 2020 | 37 | 1.040 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 7 | 2020 | 98 | 1.040 |
Why?
|
| Models, Statistical | 4 | 2014 | 164 | 1.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 6 | 2025 | 97 | 1.020 |
Why?
|
| Insurance, Health | 2 | 2026 | 167 | 1.010 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 186 | 1.000 |
Why?
|
| Adolescent | 37 | 2025 | 3464 | 0.970 |
Why?
|
| Incidence | 18 | 2026 | 1229 | 0.960 |
Why?
|
| Case-Control Studies | 21 | 2026 | 995 | 0.920 |
Why?
|
| Pain Management | 1 | 2025 | 56 | 0.880 |
Why?
|
| Naloxone | 5 | 2020 | 19 | 0.870 |
Why?
|
| Vaccination Coverage | 6 | 2024 | 68 | 0.840 |
Why?
|
| Whooping Cough | 4 | 2013 | 71 | 0.820 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 7 | 2021 | 64 | 0.820 |
Why?
|
| Middle Aged | 28 | 2026 | 7515 | 0.800 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 70 | 0.800 |
Why?
|
| Pneumococcal Vaccines | 4 | 2025 | 67 | 0.780 |
Why?
|
| Risk Assessment | 11 | 2020 | 1047 | 0.770 |
Why?
|
| Statistics as Topic | 2 | 2013 | 54 | 0.750 |
Why?
|
| Young Adult | 23 | 2026 | 2456 | 0.750 |
Why?
|
| Measles | 2 | 2021 | 25 | 0.740 |
Why?
|
| Product Surveillance, Postmarketing | 8 | 2025 | 99 | 0.730 |
Why?
|
| Decision Making | 4 | 2019 | 164 | 0.730 |
Why?
|
| Antigens | 2 | 2021 | 7 | 0.720 |
Why?
|
| Safety | 4 | 2016 | 43 | 0.710 |
Why?
|
| Vaccines, Attenuated | 4 | 2020 | 44 | 0.700 |
Why?
|
| Adjuvants, Immunologic | 2 | 2026 | 19 | 0.690 |
Why?
|
| Bias | 3 | 2019 | 90 | 0.680 |
Why?
|
| Text Messaging | 1 | 2021 | 39 | 0.650 |
Why?
|
| Reminder Systems | 1 | 2021 | 76 | 0.640 |
Why?
|
| Pregnancy | 15 | 2024 | 1555 | 0.640 |
Why?
|
| Chickenpox Vaccine | 5 | 2021 | 91 | 0.630 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2020 | 104 | 0.630 |
Why?
|
| Communicable Diseases | 1 | 2020 | 14 | 0.620 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2017 | 56 | 0.590 |
Why?
|
| Infant, Newborn | 14 | 2025 | 828 | 0.580 |
Why?
|
| Disease Outbreaks | 3 | 2015 | 36 | 0.570 |
Why?
|
| Infection | 1 | 2018 | 17 | 0.540 |
Why?
|
| Electronic Health Records | 5 | 2019 | 702 | 0.540 |
Why?
|
| Patient Compliance | 2 | 2019 | 262 | 0.540 |
Why?
|
| Abortion, Spontaneous | 4 | 2021 | 49 | 0.530 |
Why?
|
| Gastrointestinal Diseases | 2 | 2018 | 26 | 0.520 |
Why?
|
| Aged | 16 | 2026 | 5901 | 0.520 |
Why?
|
| Information Dissemination | 1 | 2017 | 43 | 0.520 |
Why?
|
| Professional-Family Relations | 2 | 2015 | 52 | 0.490 |
Why?
|
| Odds Ratio | 5 | 2019 | 569 | 0.480 |
Why?
|
| Databases, Pharmaceutical | 1 | 2016 | 6 | 0.470 |
Why?
|
| Environmental Exposure | 2 | 2015 | 120 | 0.470 |
Why?
|
| Fentanyl | 2 | 2025 | 5 | 0.460 |
Why?
|
| Immunity, Humoral | 2 | 2026 | 5 | 0.450 |
Why?
|
| Prescription Drug Diversion | 1 | 2015 | 3 | 0.440 |
Why?
|
| Hospitalization | 7 | 2020 | 816 | 0.440 |
Why?
|
| Housing | 1 | 2015 | 38 | 0.430 |
Why?
|
| Managed Care Programs | 2 | 2013 | 275 | 0.420 |
Why?
|
| Health Education | 1 | 2014 | 79 | 0.420 |
Why?
|
| Algorithms | 2 | 2014 | 210 | 0.410 |
Why?
|
| Biometry | 1 | 2014 | 13 | 0.410 |
Why?
|
| Selection Bias | 1 | 2013 | 16 | 0.400 |
Why?
|
| Sentinel Surveillance | 1 | 2013 | 12 | 0.400 |
Why?
|
| Trust | 1 | 2013 | 33 | 0.390 |
Why?
|
| Confidence Intervals | 5 | 2021 | 207 | 0.390 |
Why?
|
| Haemophilus Vaccines | 2 | 2025 | 19 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2025 | 290 | 0.370 |
Why?
|
| Cause of Death | 4 | 2026 | 171 | 0.370 |
Why?
|
| Biostatistics | 1 | 2012 | 11 | 0.360 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2012 | 5 | 0.360 |
Why?
|
| Health Services | 1 | 2013 | 100 | 0.360 |
Why?
|
| Models, Theoretical | 4 | 2020 | 66 | 0.350 |
Why?
|
| Time Factors | 8 | 2013 | 989 | 0.350 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 346 | 0.350 |
Why?
|
| Intussusception | 3 | 2014 | 16 | 0.350 |
Why?
|
| Public Health Surveillance | 3 | 2020 | 42 | 0.340 |
Why?
|
| Logistic Models | 6 | 2020 | 796 | 0.340 |
Why?
|
| Immunization | 4 | 2024 | 70 | 0.330 |
Why?
|
| Epidemiologic Research Design | 1 | 2010 | 18 | 0.330 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2010 | 13 | 0.330 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 657 | 0.330 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 1233 | 0.320 |
Why?
|
| Pandemics | 5 | 2024 | 289 | 0.320 |
Why?
|
| Risk | 11 | 2021 | 453 | 0.320 |
Why?
|
| Prescriptions | 2 | 2020 | 28 | 0.310 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 114 | 0.310 |
Why?
|
| Focus Groups | 3 | 2015 | 140 | 0.310 |
Why?
|
| Chickenpox | 1 | 2010 | 35 | 0.300 |
Why?
|
| Pertussis Vaccine | 1 | 2009 | 13 | 0.290 |
Why?
|
| Age Factors | 6 | 2020 | 814 | 0.290 |
Why?
|
| Qualitative Research | 4 | 2020 | 288 | 0.290 |
Why?
|
| Population Surveillance | 6 | 2013 | 242 | 0.290 |
Why?
|
| Mortality | 3 | 2021 | 116 | 0.290 |
Why?
|
| Computer Simulation | 4 | 2013 | 84 | 0.290 |
Why?
|
| Research Design | 4 | 2024 | 319 | 0.280 |
Why?
|
| Alcoholism | 5 | 2012 | 235 | 0.280 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 17 | 0.270 |
Why?
|
| Immunization Programs | 4 | 2022 | 65 | 0.260 |
Why?
|
| Epidemiologic Methods | 3 | 2019 | 67 | 0.260 |
Why?
|
| Risk Factors | 12 | 2020 | 3108 | 0.260 |
Why?
|
| Database Management Systems | 2 | 2020 | 14 | 0.250 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 3 | 2016 | 32 | 0.250 |
Why?
|
| Epilepsy | 1 | 2026 | 14 | 0.230 |
Why?
|
| Data Mining | 1 | 2025 | 18 | 0.230 |
Why?
|
| Methadone | 1 | 2025 | 11 | 0.230 |
Why?
|
| Haemophilus influenzae type b | 1 | 2025 | 4 | 0.230 |
Why?
|
| Haemophilus Infections | 1 | 2025 | 7 | 0.230 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2025 | 12 | 0.230 |
Why?
|
| Alcohol Drinking | 3 | 2002 | 298 | 0.220 |
Why?
|
| Pneumococcal Infections | 1 | 2025 | 43 | 0.220 |
Why?
|
| Health Services Research | 1 | 2006 | 180 | 0.220 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2025 | 40 | 0.220 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 489 | 0.220 |
Why?
|
| Heroin Dependence | 2 | 2020 | 5 | 0.220 |
Why?
|
| Health Behavior | 2 | 2019 | 332 | 0.210 |
Why?
|
| Seasons | 4 | 2024 | 114 | 0.210 |
Why?
|
| Substance-Related Disorders | 3 | 2020 | 305 | 0.210 |
Why?
|
| RNA, Viral | 1 | 2024 | 66 | 0.210 |
Why?
|
| World Health Organization | 3 | 2002 | 10 | 0.210 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 325 | 0.200 |
Why?
|
| Stillbirth | 2 | 2021 | 29 | 0.200 |
Why?
|
| Seizures | 2 | 2014 | 28 | 0.200 |
Why?
|
| Premature Birth | 2 | 2024 | 133 | 0.200 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1204 | 0.200 |
Why?
|
| Anthozoa | 1 | 2023 | 1 | 0.200 |
Why?
|
| Gestational Age | 2 | 2021 | 118 | 0.190 |
Why?
|
| Drug Prescriptions | 2 | 2015 | 137 | 0.190 |
Why?
|
| Monkeypox | 1 | 2022 | 1 | 0.190 |
Why?
|
| Smallpox Vaccine | 1 | 2022 | 6 | 0.190 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 4 | 0.190 |
Why?
|
| Eczema | 1 | 2022 | 7 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 2 | 2021 | 67 | 0.180 |
Why?
|
| Pericarditis | 1 | 2022 | 11 | 0.180 |
Why?
|
| Myocarditis | 1 | 2022 | 14 | 0.180 |
Why?
|
| Databases, Factual | 2 | 2014 | 294 | 0.180 |
Why?
|
| Cataplexy | 1 | 2022 | 6 | 0.180 |
Why?
|
| Narcolepsy | 1 | 2022 | 8 | 0.180 |
Why?
|
| Bell Palsy | 1 | 2022 | 14 | 0.180 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2022 | 17 | 0.180 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2014 | 24 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 2 | 2011 | 7 | 0.180 |
Why?
|
| Maternal Age | 1 | 2021 | 73 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1058 | 0.170 |
Why?
|
| Medical Informatics | 2 | 2019 | 34 | 0.170 |
Why?
|
| Sex Factors | 3 | 2021 | 560 | 0.170 |
Why?
|
| HIV Infections | 2 | 2024 | 708 | 0.170 |
Why?
|
| Heroin | 1 | 2020 | 4 | 0.160 |
Why?
|
| Motivation | 1 | 2021 | 103 | 0.160 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 291 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2020 | 26 | 0.160 |
Why?
|
| Telemedicine | 1 | 2024 | 190 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 36 | 0.160 |
Why?
|
| London | 1 | 2020 | 6 | 0.160 |
Why?
|
| Congresses as Topic | 1 | 2020 | 13 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2020 | 210 | 0.150 |
Why?
|
| Bacterial Vaccines | 2 | 2023 | 9 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.150 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 113 | 0.150 |
Why?
|
| California | 2 | 2024 | 2244 | 0.150 |
Why?
|
| Pregnant Women | 1 | 2020 | 41 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 1887 | 0.150 |
Why?
|
| Vaccination Refusal | 1 | 2019 | 10 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 515 | 0.150 |
Why?
|
| Asthma | 1 | 2022 | 375 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 141 | 0.150 |
Why?
|
| Parenting | 1 | 2019 | 29 | 0.150 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 5 | 0.140 |
Why?
|
| Chronic Disease | 2 | 2013 | 382 | 0.140 |
Why?
|
| Croup | 1 | 2018 | 4 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2019 | 142 | 0.140 |
Why?
|
| Otitis Media | 1 | 2018 | 19 | 0.140 |
Why?
|
| Infant Mortality | 1 | 2018 | 14 | 0.140 |
Why?
|
| Analysis of Variance | 4 | 2008 | 120 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2017 | 22 | 0.130 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 197 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 58 | 0.130 |
Why?
|
| Pneumonia | 1 | 2017 | 47 | 0.130 |
Why?
|
| Poisson Distribution | 3 | 2014 | 84 | 0.130 |
Why?
|
| Measles Vaccine | 1 | 2017 | 17 | 0.130 |
Why?
|
| Socioeconomic Factors | 5 | 2019 | 571 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2017 | 102 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 55 | 0.120 |
Why?
|
| Fever | 1 | 2017 | 52 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2017 | 88 | 0.120 |
Why?
|
| Acute Disease | 2 | 2008 | 144 | 0.120 |
Why?
|
| Immunization, Secondary | 3 | 2014 | 58 | 0.120 |
Why?
|
| Ambulatory Care | 2 | 2018 | 205 | 0.120 |
Why?
|
| Sex Distribution | 3 | 2017 | 164 | 0.120 |
Why?
|
| Age Distribution | 3 | 2017 | 221 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2026 | 1186 | 0.110 |
Why?
|
| General Practice | 1 | 2015 | 5 | 0.110 |
Why?
|
| Seizures, Febrile | 2 | 2013 | 42 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2015 | 107 | 0.110 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 63 | 0.110 |
Why?
|
| User-Computer Interface | 1 | 2014 | 21 | 0.110 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2013 | 15 | 0.110 |
Why?
|
| Community Health Services | 1 | 2015 | 68 | 0.110 |
Why?
|
| Program Development | 1 | 2014 | 62 | 0.110 |
Why?
|
| Prisoners | 1 | 2015 | 53 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 160 | 0.100 |
Why?
|
| Needle Sharing | 2 | 2005 | 2 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2005 | 21 | 0.100 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2014 | 21 | 0.100 |
Why?
|
| Communication | 1 | 2015 | 183 | 0.100 |
Why?
|
| Viral Vaccines | 1 | 2014 | 12 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2016 | 693 | 0.100 |
Why?
|
| Bacterial Capsules | 2 | 2025 | 7 | 0.100 |
Why?
|
| Mass Vaccination | 1 | 2013 | 22 | 0.100 |
Why?
|
| Hepatitis C | 2 | 2005 | 54 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2013 | 112 | 0.100 |
Why?
|
| Prehypertension | 1 | 2013 | 21 | 0.100 |
Why?
|
| Genes, MHC Class II | 1 | 2012 | 2 | 0.100 |
Why?
|
| Diphtheria | 1 | 2012 | 13 | 0.090 |
Why?
|
| Tetanus | 1 | 2012 | 23 | 0.090 |
Why?
|
| Prescription Drugs | 1 | 2013 | 29 | 0.090 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 85 | 0.090 |
Why?
|
| Adenylyl Cyclases | 2 | 2002 | 2 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 60 | 0.090 |
Why?
|
| Prisons | 1 | 2012 | 28 | 0.090 |
Why?
|
| Blood Pressure | 1 | 2013 | 278 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 117 | 0.090 |
Why?
|
| Community Health Centers | 1 | 2012 | 58 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2012 | 92 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2012 | 155 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2008 | 76 | 0.080 |
Why?
|
| Autistic Disorder | 1 | 2011 | 117 | 0.080 |
Why?
|
| Anemia, Hemolytic | 1 | 2009 | 2 | 0.080 |
Why?
|
| Linear Models | 2 | 2008 | 187 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 410 | 0.070 |
Why?
|
| Hepatitis B Vaccines | 1 | 2009 | 44 | 0.070 |
Why?
|
| Registries | 2 | 2008 | 449 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2009 | 36 | 0.070 |
Why?
|
| Health Surveys | 1 | 2009 | 226 | 0.070 |
Why?
|
| Hypertension | 1 | 2013 | 475 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2008 | 6 | 0.070 |
Why?
|
| Splenectomy | 1 | 2008 | 2 | 0.070 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2008 | 2 | 0.070 |
Why?
|
| Communicable Disease Control | 1 | 2008 | 19 | 0.070 |
Why?
|
| Platelet Count | 1 | 2008 | 10 | 0.070 |
Why?
|
| Mass Screening | 1 | 2013 | 670 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 191 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2015 | 261 | 0.060 |
Why?
|
| Disease Progression | 1 | 2008 | 252 | 0.060 |
Why?
|
| Prognosis | 1 | 2008 | 568 | 0.060 |
Why?
|
| Stroke | 1 | 2009 | 297 | 0.060 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2006 | 77 | 0.060 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2025 | 28 | 0.060 |
Why?
|
| Streptococcus pneumoniae | 1 | 2025 | 21 | 0.060 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2025 | 29 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2005 | 43 | 0.050 |
Why?
|
| Health Personnel | 2 | 2015 | 132 | 0.050 |
Why?
|
| Oceans and Seas | 1 | 2023 | 1 | 0.050 |
Why?
|
| Coral Reefs | 1 | 2023 | 1 | 0.050 |
Why?
|
| El Nino-Southern Oscillation | 1 | 2023 | 1 | 0.050 |
Why?
|
| Ecosystem | 1 | 2023 | 4 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 160 | 0.050 |
Why?
|
| Family Characteristics | 1 | 2023 | 69 | 0.050 |
Why?
|
| Cooperative Behavior | 2 | 2014 | 84 | 0.050 |
Why?
|
| Prevalence | 2 | 2021 | 785 | 0.050 |
Why?
|
| Vaccines, Combined | 2 | 2014 | 80 | 0.050 |
Why?
|
| Animals | 1 | 2023 | 237 | 0.050 |
Why?
|
| Monoamine Oxidase | 1 | 2002 | 1 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2002 | 3 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2002 | 20 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2022 | 66 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 129 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 39 | 0.040 |
Why?
|
| Body Water | 1 | 2001 | 3 | 0.040 |
Why?
|
| Transferrin | 1 | 2001 | 4 | 0.040 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2001 | 1 | 0.040 |
Why?
|
| Radon | 1 | 2001 | 2 | 0.040 |
Why?
|
| Policy | 1 | 2021 | 19 | 0.040 |
Why?
|
| Health Facilities | 1 | 2020 | 16 | 0.040 |
Why?
|
| Mutation | 1 | 2001 | 86 | 0.040 |
Why?
|
| Smoking | 1 | 2002 | 373 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 145 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2021 | 255 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 24 | 0.040 |
Why?
|
| Psychometrics | 1 | 2019 | 114 | 0.040 |
Why?
|
| Ethnic Groups | 1 | 2021 | 418 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 21 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 23 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 84 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 46 | 0.030 |
Why?
|
| Outpatients | 1 | 2018 | 99 | 0.030 |
Why?
|
| Family Health | 1 | 2017 | 40 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2001 | 925 | 0.030 |
Why?
|
| Biomarkers | 3 | 2002 | 284 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 516 | 0.030 |
Why?
|
| Neoplasms | 1 | 2001 | 447 | 0.030 |
Why?
|
| Contraindications | 1 | 2014 | 13 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 41 | 0.020 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2013 | 18 | 0.020 |
Why?
|
| Anaphylaxis | 1 | 2013 | 15 | 0.020 |
Why?
|
| Fetal Mortality | 1 | 2013 | 2 | 0.020 |
Why?
|
| Fetal Death | 1 | 2013 | 7 | 0.020 |
Why?
|
| Vaccines, Conjugate | 1 | 2013 | 59 | 0.020 |
Why?
|
| Vaccines, Acellular | 1 | 2012 | 11 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 32 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2012 | 13 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 262 | 0.020 |
Why?
|
| Hepatitis A Vaccines | 1 | 2012 | 15 | 0.020 |
Why?
|
| Rotavirus Infections | 1 | 2012 | 33 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Safety Management | 1 | 2011 | 13 | 0.020 |
Why?
|
| Family | 1 | 2012 | 99 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 319 | 0.020 |
Why?
|
| Mental Health | 1 | 2012 | 161 | 0.020 |
Why?
|
| Suicide | 1 | 2012 | 114 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 195 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 185 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2012 | 393 | 0.020 |
Why?
|
| Syringes | 1 | 2005 | 1 | 0.010 |
Why?
|
| Cocaine-Related Disorders | 1 | 2005 | 3 | 0.010 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2005 | 2 | 0.010 |
Why?
|
| Social Identification | 1 | 2005 | 5 | 0.010 |
Why?
|
| Methamphetamine | 1 | 2005 | 3 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 47 | 0.010 |
Why?
|
| Social Environment | 1 | 2005 | 77 | 0.010 |
Why?
|
| Medical Record Linkage | 1 | 2004 | 35 | 0.010 |
Why?
|
| Illinois | 1 | 2003 | 8 | 0.010 |
Why?
|
| Equipment Contamination | 1 | 2003 | 2 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 358 | 0.010 |
Why?
|
| Affinity Labels | 1 | 2002 | 1 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 7 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 8 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 45 | 0.010 |
Why?
|
| Marijuana Abuse | 1 | 2002 | 33 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2001 | 2 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 2001 | 10 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 2001 | 19 | 0.010 |
Why?
|
| Causality | 1 | 2001 | 32 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 653 | 0.010 |
Why?
|